Mediation effect of herpes zoster derived by statin use on cardiovascular disease risk
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Although statins are widely used to reduce the risk of cardiovascular disease (CVD) including stroke and myocardial infarction (MI), it is reported that statin use increases the incidence of herpes zoster (HZ) that is associated with increased risk of CVD. So, we evaluated the mediation effect of HZ caused by statin use on CVD. Methods: We analyzed a prospective cohort from the National Health Insurance Service-database of South Korea. All individuals received a medical check-up and were followed-up from 2002 to 2013. Results: A total of 275,382 individuals > 40 years old were followed up for 11 years from 2003. Of these, 11,415 people (4%) were classified as statin users and 263,967 (96%) as non-statin users. Those who used statins had significantly lower risks of cardiovascular events, stroke, and MI compared with non-statin users; the adjusted hazard ratios in the multivariate analysis were 0.90 (95% confidence interval [CI], 0.82 to 0.98), 0.88 (95% CI, 0.80 to 0.98), and 0.91 (95% CI, 0.79 to 1.07), respectively. When we calculated the mediating effect of cardiovascular events by statin use through HZ, 11.6% of the total beneficial effect of cardiovascular events by statin use was mitigated through the occurrence of HZ caused by statin use. This mediating effect was higher in the younger age group (< 60 years). Conclusions: This study showed that statin use reduced CVD by 10%, but the protective effect of statin use against CVD was mitigated by approximately 10% through the development of HZ caused by statin use.
Abstract
Background/Aims: Although statins are widely used to reduce the risk of cardiovascular disease (CVD) including stroke and myocardial infarction (MI), it is reported that statin use increases the incidence of herpes zoster (HZ) that is associated with increased risk of CVD. So, we evaluated the mediation effect of HZ caused by statin use on CVD. Methods: We analyzed a prospective cohort from the National Health Insurance Service-database of South Korea. All individuals received a medical check-up and were followed-up from 2002 to 2013. Results: A total of 275,382 individuals > 40 years old were followed up for 11 years from 2003. Of these, 11,415 people (4%) were classified as statin users and 263,967 (96%) as non-statin users. Those who used statins had significantly lower risks of cardiovascular events, stroke, and MI compared with non-statin users; the adjusted hazard ratios in the multivariate analysis were 0.90 (95% confidence interval [CI], 0.82 to 0.98), 0.88 (95% CI, 0.80 to 0.98), and 0.91 (95% CI, 0.79 to 1.07), respectively. When we calculated the mediating effect of cardiovascular events by statin use through HZ, 11.6% of the total beneficial effect of cardiovascular events by statin use was mitigated through the occurrence of HZ caused by statin use. This mediating effect was higher in the younger age group (< 60 years). Conclusions: This study showed that statin use reduced CVD by 10%, but the protective effect of statin use against CVD was mitigated by approximately 10% through the development of HZ caused by statin use.
참고문헌 (18)
- Kwon SU, "Risk of stroke and transient ischaemic attack after herpes zoster", Clin Microbiol Infect, 22, pp.542~548 (2016)
- Kim MC, "Herpes zoster increases the risk of stroke and myocardial infarction", J Am Coll Cardiol, 70, pp.295~296 (2017)
- Breuer J, "Herpes zoster as a risk factor for stroke and TIA : a retrospective cohort study in the UK", Neurology, 82, pp.206~212 (2014)
- Langan SM, "Risk of stroke following herpes zoster : a self-controlled case-series study", Clin Infect Dis, 58, pp.1497~1503 (2014)
- Yawn BP, "Risk of stroke and myocardial infarction after herpes zoster in older adults in a US community population", Mayo Clin Proc, 91, pp.33~44 (2016)
- Chou R, "Statins for prevention of cardiovascular disease in adults : evidence report and systematic review for the US Preventive services task force", JAMA, 316, pp.2008~2024 (2016)
- Antoniou T, "Statins and the risk of herpes zoster : a population-based cohort study", Clin Infect Dis, 58, pp.350~356 (2014)
- Chen HH, "Statins can increase the risk of herpes zoster infection in Asia", Eur J Clin Microbiol Infect Dis, 34, pp.1451~1458 (2015)
- Matthews A, "Statin use and the risk of herpes zoster : a nested case-control study using primary care data from the U. K. Clinical Research Practice Datalink", Br J Dermatol, 175, pp.1183~1194 (2016)
- Lee J, "Cohort profile:the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea", Int J Epidemiol, 46, pp.e15~ (2017)
- VanderWeele TJ, "Explanation in Causal Inference: Methods for Mediation and Interaction" (2015), Oxford University Press
- Yang YW, "Risk of herpes zoster among patients with chronic obstructive pulmonary disease : a population-based study", CMAJ, 183, pp.E275~E280 (2011)
- Valeri L, "Mediation analysis allowing for exposure-mediator interactions and causal interpretation : theoretical assumptions and implementation with SAS and SPSS macros", Psychol Methods, 18, pp.137~150 (2013)
- Charo IF, "Anti-inflammatory therapeutics for the treatment of atherosclerosis", Nat Rev Drug Discov, 10, pp.365~376 (2011)
- Lal H, "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults", N Engl J Med, 372, pp.2087~2096 (2015)
- "Korea National Health and Nutrition Examination Survey 2013" (2019)[URL]
- Donahue JG, "The incidence of herpes zoster", Arch Intern Med, 155, pp.1605~1609 (1995)
- Mullooly JP, "Incidence of herpes zoster, 1997-2002", Epidemiol Infect, 133, pp.245~253 (2005)